Seborrheic Keratosis Treatment Market Report 2024-2030, Featuring Comprehensive Profiles of Aclaris Therapeutics, Alma Lasers, BIOLASE, BioLineRx, DermBiont, Novartis and Pulse Biosciences
Pulse Biosciences | 10-Q: Q2 2024 Earnings Report
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Earnings Call: Pulse Biosciences Details Progress on Nano-PFA Devices
Earnings Call Summary | Pulse Biosciences(PLSE.US) Q2 2024 Earnings Conference
Stocks to Watch: BuzzFeed, FreightCar America, Pulse Bioscience
Boxman : Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company’s Cardiac Surgery System to successfully treat two patients with atrial fibrillation at St. Antonius Hospital, Nieuwegein, The Netherlands. Dr. Van Putte was joined by colleagues and Pulse Biosciences’ Chief Medical Officer, Cardiac Surgery, Dr. Gan Dunnington and Chief Science Officer, Cardiac Surgery, Dr. Niv Ad during the concomitant procedure. The first-in-human feasibility study is a multicenter study of up to 30 patients that will include an endocardial catheter-based remapping to confirm chronic isolation at approximately three months post treatment